Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
09:06am, Wednesday, 11'th Feb 2026
CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.
CorMedix (NASDAQ:CRMD) to Buyback $75.00 million in Outstanding Stock
01:02am, Tuesday, 03'rd Feb 2026
CorMedix (NASDAQ: CRMD - Get Free Report) declared that its board has initiated a stock repurchase plan on Monday, February 2nd, RTT News reports. The company plans to repurchase $75.00 million in sha
CorMedix Therapeutics Announces Share Repurchase Program
08:30am, Monday, 02'nd Feb 2026
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
09:40am, Friday, 30'th Jan 2026
CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
08:30am, Thursday, 29'th Jan 2026
BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre
Hussman Strategic Advisors Inc. Purchases 252,000 Shares of CorMedix Inc $CRMD
05:51am, Wednesday, 28'th Jan 2026
Hussman Strategic Advisors Inc. increased its position in CorMedix Inc (NASDAQ: CRMD) by 400.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?
12:01pm, Friday, 23'rd Jan 2026
CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?
10:40am, Tuesday, 20'th Jan 2026
CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
11:28am, Monday, 19'th Jan 2026
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key pred
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?
09:40am, Thursday, 15'th Jan 2026
CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation
09:57am, Wednesday, 14'th Jan 2026
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning pote
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01:26am, Tuesday, 13'th Jan 2026
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Are Investors Undervaluing CorMedix (CRMD) Right Now?
10:40am, Friday, 09'th Jan 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:30am, Friday, 09'th Jan 2026
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre
Why is CorMedix stock crashing today: is it worth buying on the dip?
01:37pm, Thursday, 08'th Jan 2026
Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026. The announcement isn't sitting well with shareholders, prima
